TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38798539

Group type: EXPERIMENTAL
Intervention: 8-h time restricted eating (TRE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Daily calorie restriction (CR)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postmenopausal females (Estradiol, Estrone, Progesterone)
Number of subjects: 90
Study: 38798709

Group type: EXPERIMENTAL
Intervention: Automated sleep staging algorithm (SeqSleepNet) using three channels: C4-A1, EOG, and chin EMG.
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Automated sleep staging algorithm (SeqSleepNet) in children with DRE.
Number of subjects: 176
Study: 38798893

Group type: EXPERIMENTAL
Intervention: Xpert-Ultra assay with stool samples
Number of subjects: 563

Group type: EXPERIMENTAL
Intervention: Xpert-Ultra assay with urine samples
Number of subjects: 563

Group type: COMPARATOR
Intervention: Reference standard (RS)
Number of subjects: 563
Study: 38798902

Group type: EXPERIMENTAL
Intervention: Movement behavior compositions (12.1 h of sleep, 4.7 h of sedentary time, 5.6 h of light physical activity, 1.7 h of MVPA)
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Movement behavior compositions
Number of subjects: 388
Study: 38799274

Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg (up to once daily as needed for 52 weeks)
Number of subjects: 1800
Study: 38799276

Group type: EXPERIMENTAL
Intervention: MEMS bottles containing opioid medication for a 90-day period
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard medication bottles
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: MEMS data
Number of subjects: 28
Study: 38799438

Group type: EXPERIMENTAL
Intervention: CHM granules (9g/sachet, two times daily) for 7 days
Number of subjects: 2163

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: CHM granules
Number of subjects: 2163
Study: 38800061

Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy for insomnia (iCBT-I) for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: internet-based cognitive behavioral therapy for insomnia (iCBT-I)
Number of subjects: 0
Study: 38800121

Group type: EXPERIMENTAL
Intervention: Polysaccharide hemostatic (PH) topical product
Number of subjects: 324

Group type: COMPARATOR
Intervention: Microporous polysaccharide hemospheres (MPH)
Number of subjects: 324
Study: 38800350

Group type: EXPERIMENTAL
Intervention: 5-minute handgrip and isometric exercises (pulling and pushing)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10-minute healthy-diet videos
Number of subjects: 30
Study: 38800408

Group type: EXPERIMENTAL
Intervention: DPCP 0.04% ointment applied twice weekly to four in-transit metastases, concurrent with pembrolizumab 300 mg every three weeks.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: DPCP 0.04% ointment
Number of subjects: 1
Study: 38800632

Group type: EXPERIMENTAL
Intervention: O-BD
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: O-BD (aged under 12 years)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: O-BD (aged 12 years and over)
Number of subjects: 393
Study: 38800678

Group type: EXPERIMENTAL
Intervention: GAD-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PHQ-2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GAD-2 and PHQ-2
Number of subjects: 0
Study: 38800802

Group type: EXPERIMENTAL
Intervention: Sintilimab plus chemotherapy
Number of subjects: 689
Study: 38800822

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 80 mg triamcinolone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study: 38801306

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) with high-frequency oscillatory ventilation (HFOV)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Supine positioning with conventional mechanical ventilation (CMV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Prone positioning (PP) with conventional mechanical ventilation (CMV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Supine positioning with high-frequency oscillatory ventilation (HFOV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 600
Study: 38801597

Group type: EXPERIMENTAL
Intervention: Prolactinoma patients
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 38801606

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg twice daily for 16 weeks plus existing topical therapy
Number of subjects: 134
Study: 38801641

Group type: EXPERIMENTAL
Intervention: Standardized Chinese medicine (CM) treatment ≥3 months
Number of subjects: 2001

Group type: COMPARATOR
Intervention: Standard medical treatment (non-CM cohort)
Number of subjects: 2001
Study: 38801774

Group type: EXPERIMENTAL
Intervention: Combined extracorporeal shock-wave lithotripsy (ESWL) and endoscopic retrograde pancreatography (ERP)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Sham procedures
Number of subjects: 106
Study: 38801826

Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF-RSV preF protein (one intramuscular injection)
Number of subjects: 5782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5782
Study: 38801945

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT) at 25-40 Gy/5 fractions per tumor volume
Number of subjects: 85

Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT) at 37.5 Gy/15 fractions
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy (SRT)
Number of subjects: 85
Study: 38802053

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 466

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 466
Study: 38802273

Group type: EXPERIMENTAL
Intervention: Digital health technologies, real-time self-reports, and qualitative interview data
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Self-reports of mental and physical fatigue via smartphone app
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Validated fatigue and affect questionnaires
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: End-of-study interviews
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Feedback session offered to participants
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: ECG patches and wearable bracelet
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Wearable bracelet and environment beacons
Number of subjects: 40
Study: 38802281

Group type: EXPERIMENTAL
Intervention: Internet-CBT
Number of subjects: 90

Group type: COMPARATOR
Intervention: TAU+ME
Number of subjects: 90
Study: 38802370

Group type: EXPERIMENTAL
Intervention: High environmental pollution exposure
Number of subjects: 359

Group type: COMPARATOR
Intervention: Medium environmental pollution exposure
Number of subjects: 359

Group type: COMPARATOR
Intervention: Low environmental pollution exposure
Number of subjects: 359
Study: 38802399

Group type: EXPERIMENTAL
Intervention: QCS-based patient stratification
Number of subjects: 151

Group type: COMPARATOR
Intervention: Manual scoring based on ASCO/CAP guidelines
Number of subjects: 151
Study: 38802569

Group type: EXPERIMENTAL
Intervention: Human amniotic epithelial stem cells (hAESCs) injected on day -1 or day 7 post-PBMC infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study: 38802634

Group type: EXPERIMENTAL
Intervention: Venglustat in combination with imiglucerase
Number of subjects: 11
Study: 38802635

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38802811

Group type: EXPERIMENTAL
Intervention: WHO-PEN interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 0
Study: 38802866

Group type: EXPERIMENTAL
Intervention: CPM therapy (n=48)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (CG) (n=47)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: CPM therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 95
Study: 38802888

Group type: EXPERIMENTAL
Intervention: HFRT with SIB (40 Gy in 15 fractions, SIB of 48 Gy in 15 fractions to the tumor bed)
Number of subjects: 2904

Group type: COMPARATOR
Intervention: CFRT with sequential boost (50 Gy in 25 fractions, sequential boost of 10 Gy in 5 fractions to the tumor bed)
Number of subjects: 2904
Study: 38803220

Group type: EXPERIMENTAL
Intervention: Bortezomib-based chemotherapy plus therapeutic plasmapheresis (TPP) with 4% human albumin solution
Number of subjects: 119
Study: 38803252

Group type: EXPERIMENTAL
Intervention: Virtual community of practice (VCoP) - online social interaction for 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individualised online self-management education (control) - delivered individually for 12 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VCoP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individualised online self-management education (control)
Number of subjects: 0
Study: 38803266

Group type: EXPERIMENTAL
Intervention: Strength exercise (n=54)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (n=53)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Usual care (n=54)
Number of subjects: 161
Study: 38803412

Group type: EXPERIMENTAL
Intervention: MK-5475
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 38803549

Group type: EXPERIMENTAL
Intervention: Transanal irrigation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 38803611

Group type: EXPERIMENTAL
Intervention: Time for Living and Caring (TLC) intervention
Number of subjects: 0
Study: 38803628

Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg with a targeted prescribing pathway
Number of subjects: 392

Group type: COMPARATOR
Intervention: Standard SWMS care
Number of subjects: 392
Study: 38803637

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Tablet
Number of subjects: 50
Study: 38803693

Group type: EXPERIMENTAL
Intervention: Mediterranean Ketogenic Nutrition Adherence (MKNA) Program
Number of subjects: 58

Group type: COMPARATOR
Intervention: MKN Education (MKNE) program
Number of subjects: 58
Study: 38803811

Group type: EXPERIMENTAL
Intervention: Slow Art Plus intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 38803995

Group type: EXPERIMENTAL
Intervention: Urine exosomal peptides after thyroidectomy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Serum proteins and urine exosomal peptides
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Known risk factors for high-risk thyroid cancer
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Concentrations of serum proteins or urine exosomal peptides
Number of subjects: 70
Study: 38804134

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 168
Study: 38804148

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 38804183

Group type: EXPERIMENTAL
Intervention: Personalised lifestyle programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38804212

Group type: EXPERIMENTAL
Intervention: AZD3366
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 38804514

Group type: EXPERIMENTAL
Intervention: Felzartamab (16 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Felzartamab
Number of subjects: 22
Study: 38804517

Group type: EXPERIMENTAL
Intervention: Plozasiran 10 mg (quarterly dose)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Plozasiran 25 mg (quarterly dose)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Plozasiran 50 mg (quarterly dose)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Plozasiran 50 mg (half-yearly dose)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 38804779

Group type: EXPERIMENTAL
Intervention: Peanut consumption group (ad libitum peanut consumption from infancy to age 5 years)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Peanut avoidance group (avoided peanuts from infancy to age 5 years)
Number of subjects: 508
Study: 38804782

Group type: EXPERIMENTAL
Intervention: CK0801 Treg cell therapy
Number of subjects: 9
Study: 38804790

Group type: EXPERIMENTAL
Intervention: Olgotrelvir 600 mg twice daily for 5 days
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1212
Study: 38804903

Group type: EXPERIMENTAL
Intervention: Tobacco Heating System (THS) 2.2, non-mentholated
Number of subjects: 984

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 984
Study: 38805037

Group type: EXPERIMENTAL
Intervention: Chidamide maintenance
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 85

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 85
Study: 38805069

Group type: EXPERIMENTAL
Intervention: GaAs 904 nm PBM at 10 J/cm²
Number of subjects: 0

Group type: COMPARATOR
Intervention: GaAs 904 nm PBM (all dosages)
Number of subjects: 0
Study: 38805199

Group type: EXPERIMENTAL
Intervention: Twice-daily meditation
Number of subjects: 247

Group type: COMPARATOR
Intervention: Once-daily meditation
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Mobile app introduction
Number of subjects: 247

Group type: COMPARATOR
Intervention: Therapist call introduction
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: App-based management of increasing symptoms
Number of subjects: 247

Group type: COMPARATOR
Intervention: Therapist call management of increasing symptoms
Number of subjects: 247
Study: 38805207

Group type: EXPERIMENTAL
Intervention: Early DOAC initiation (within 48 hours for minor/moderate stroke; days 6-7 for major stroke)
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Late DOAC initiation (days 3-4 for minor stroke; days 6-7 for moderate stroke; days 12-14 for major stroke)
Number of subjects: 1962

Group type: EXPERIMENTAL
Intervention: Early DOAC initiation
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Late DOAC initiation
Number of subjects: 1962
Study: 38805213

Group type: EXPERIMENTAL
Intervention: GLPG3667, a selective ATP competitive TYK2 inhibitor, dosage and duration not available
Number of subjects: 0
Study: 38805216

Group type: EXPERIMENTAL
Intervention: Immediate-intensive atorvastatin (80 mg daily on days 1-21; 40 mg daily on days 22-90)
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Delayed-intensive statin (placebo for days 1-3, followed by atorvastatin 40 mg daily on days 4-21, and then atorvastatin 40 mg daily on days 22-90)
Number of subjects: 6100

Group type: EXPERIMENTAL
Intervention: Immediate-intensive atorvastatin
Number of subjects: 6100

Group type: COMPARATOR
Intervention: Delayed-intensive statin
Number of subjects: 6100
Study: 38805228

Group type: EXPERIMENTAL
Intervention: Vaginal natural progesterone therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 38805242

Group type: EXPERIMENTAL
Intervention: SHR-1703 (20 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SHR-1703 (75 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SHR-1703 (150 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SHR-1703 (300 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SHR-1703 (400 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 38805251

Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled BP monitoring and digital cognitive assessments for 6 months
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bluetooth-enabled BP monitoring
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Digital cognitive assessments
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bluetooth self-measured BP (SMBP) monitoring
Number of subjects: 71
Study: 38805253

Group type: EXPERIMENTAL
Intervention: AI-based lifestyle coaching program delivered via SMS and mobile app
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: AI-based lifestyle coaching program
Number of subjects: 141
Study: 38805264

Group type: EXPERIMENTAL
Intervention: Patient Preferences for Patient Participation (4Ps) tool
Number of subjects: 949
Study: 38805527

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of dorsal nerve roots via epidural lead placement
Number of subjects: 16
Study: 38805536

Group type: EXPERIMENTAL
Intervention: Midazolam sedation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No sedation (control group)
Number of subjects: 0
Study: 38805559

Group type: EXPERIMENTAL
Intervention: Immunochromatographic-test (ICT)
Number of subjects: 58
Study: 38805668

Group type: EXPERIMENTAL
Intervention: STRIDE
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 1171
Study: 38805733

Group type: EXPERIMENTAL
Intervention: Low-level light therapy (LLLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment (placebo)
Number of subjects: 0
Study: 38805784

Group type: EXPERIMENTAL
Intervention: WM training (12 half-hour sessions)
Number of subjects: 30
Study: 38805853

Group type: EXPERIMENTAL
Intervention: Adjuvanted cHA-based IIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LAIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unadjuvanted cHA-based IIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38806045

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine TAK-003 (high-dose formulation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine TAK-003 (standard approved formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38806190

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab 40 mg every other week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: upadacitinib
Number of subjects: 0
Study: 38806195

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus chemotherapy
Number of subjects: 997

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 997
Study: 38806315

Group type: EXPERIMENTAL
Intervention: IDRA tool risk assessment
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: IDRA tool
Number of subjects: 145
Study: 38806421

Group type: EXPERIMENTAL
Intervention: Multicomponent care pathway
Number of subjects: 0
Study: 38806430

Group type: EXPERIMENTAL
Intervention: Bronchoscopic thermal vapour ablation (BTVA) treatment with the InterVapor system together with standard medical management
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard medical management alone (according to GOLD guidelines)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: BTVA treatment
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard medical management alone
Number of subjects: 224
Study: 38806467

Group type: EXPERIMENTAL
Intervention: Intermittent fasting and protein pacing (IF-P)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Calorie-restricted (CR) diet
Number of subjects: 41
Study: 38806504

Group type: EXPERIMENTAL
Intervention: NOX-A12 (200/400/600 mg per week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NOX-A12 (600 mg per week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NOX-A12 (various doses)
Number of subjects: 10
Study: 38806700

Group type: EXPERIMENTAL
Intervention: BI 1467335 10 mg once daily for 12 weeks
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 38806873

Group type: EXPERIMENTAL
Intervention: Midazolam injection via needle-free auto-injector ZENEO (10 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional syringe midazolam injection (10 mg)
Number of subjects: 40
Study: 38807042

Group type: EXPERIMENTAL
Intervention: Video streaming used during the call
Number of subjects: 113

Group type: COMPARATOR
Intervention: No video streaming used during the call
Number of subjects: 113
Study: 38807063

Group type: EXPERIMENTAL
Intervention: Structured Problem Solving (SPS) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 38807091

Group type: EXPERIMENTAL
Intervention: Peer-led community-based intervention providing sexual and reproductive health (SRH) services with a prevention points card (PPC) system.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control arm (no intervention).
Number of subjects: 20
Study: 38807116

Group type: EXPERIMENTAL
Intervention: VR-based simulation training on geriatric oral health care (implemented twice at two weeks apart)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 50
Study: 38807146

Group type: EXPERIMENTAL
Intervention: TG103 (15.0 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TG103 (22.5 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TG103 (30.0 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 38807160

Group type: EXPERIMENTAL
Intervention: Pulpotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pulpectomy
Number of subjects: 50
Study: 38807165

Group type: EXPERIMENTAL
Intervention: Interaction-focused music therapy with cancer-affected children and their significant others (INMUT-KB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Music therapy only with the child (MUT-K)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Wait-list group (WLG)
Number of subjects: 52
Study: 38807183

Group type: EXPERIMENTAL
Intervention: Social memory task administered in presence-only context
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Social memory task administered in observation context
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment measuring social interactions and abilities
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multiple comparative case study
Number of subjects: 92